Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
International Journal of Clinical Oncology
Erschienen in: International Journal of Clinical Oncology 6/2010

01.12.2010 | Original Article

Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors

verfasst von: Pierre Heudel, Sebastien Cimarelli, Anthony Montella, Catherine Bouteille, Thomas Mognetti

Erschienen in: International Journal of Clinical Oncology | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

The aim of the study was to analyze in breast tumors the correlation between [18F]fluorodeoxyglucose (FDG) uptake assessed by positron emission tomography (PET) and histopathological and immunohistochemical prognostic factors.

Methods

FDG-PET combined with computed tomography (CT) was performed before surgery in 45 women with biopsy-proven primary breast cancer. The standardized uptake value (SUV) was compared with histopathological findings after surgery.

Results

A positive relationship was found between SUV and histological grade (p < 0.0001), histological type (p = 0.001), tumor size (p < 0.0435), estrogen receptor status (p < 0.0005), and progesterone receptor status (p = 0.002). FDG-PET/CT revealed unknown distant metastatic lesions in 2 of 12 patients with triple-negative breast cancer. The sensitivity of FDG-PET/CT for detecting axillary lymph node metastases was, respectively, 21% and 100% for pN1 and pN2 cases, whereas specificity was 100% for pN0.

Conclusion

SUV, a preoperative and noninvasive metabolic parameter, correlates with other known prognostic factors in breast cancer. This study provides valuable insight into the usefulness of FDG-PET/CT for preoperative staging of patients with triple-negative and poorly differentiated breast tumors but not for evaluating axillary lymph nodes and lobular carcinomas.
Literatur
1.
2.
Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef
3.
Wahl RL, Siegel BA, Coleman RE et al (2004) Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 22:277–285PubMedCrossRef
4.
Veronesi U, De Cicco C, Galimberti VE et al (2007) A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 18:473–478PubMedCrossRef
5.
Heusner TA, Kuemmel S, Hahn S et al (2009) Diagnostic value of full-dose FDG-PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging 36:1543–1550PubMedCrossRef
6.
Avril N, Rose CA, Schelling M et al (2000) Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 18:3495–3502PubMed
7.
Dose Schwarz J, Bader M, Jenicke L et al (2005) Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 467:1144–1150
8.
Avril N, Schelling M, Dose J et al (1999) Utility of PET in breast cancer. Clin Positron Imaging 2:261–271PubMedCrossRef
9.
Baum RP, Przetak C (2001) Evaluation of therapy response in breast and ovarian cancer patients by positron emission tomography (PET). Q J Nucl Med 45:257–268PubMed
10.
Wilcoxon F (1945) Individual comparisons by ranking methods. Biometrics Bull 1:80–83CrossRef
11.
Kruskal WH, Wallis WA (1952) Use of ranks in one-criterion variance analysis. J Am Stat Assoc 47:583–621CrossRef
12.
Singletary SE, Allred C, Ashley P et al (2002) Revision of the American joint Committee on cancer staging system for breast cancer. J Clin Oncol 20:3628–3636PubMedCrossRef
13.
Oshida M, Uno K, Suzuki M et al (1998) Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-d-glucose. Cancer 82:2227–2234PubMedCrossRef
14.
Avril N, Menzel M, Dose J et al (2001) Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 42:9–16PubMed
15.
Bos R, van Der Hoeven JJ, van Der Wall E et al (2002) Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20:379–387PubMedCrossRef
16.
Buck A, Schirrmeister H, Kuhn T et al (2002) FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 29:1317–1323PubMedCrossRef
17.
Cermik TF, Mavi A, Basu S et al (2008) Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer. Eur J Nucl Med Mol Imaging 35:475–483PubMedCrossRef
18.
Avril N, Bense S, Ziegler SI et al (1997) Breast imaging with fluorine-18-FDG PET: quantitative image analysis. J Nucl Med 38:1186–1191PubMed
19.
Crowe JP, Adler LP, Shenk RR et al (1994) Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol 1:132–140PubMedCrossRef
20.
Inoue T, Yutani K, Taguchi T et al (2004) Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-deoxy-2-fluoro-d-glucose-positron emission tomography. J Cancer Res Clin Oncol 130:273–278PubMedCrossRef
21.
Gil-Rendo A, Martinez-Regueira F, Zornoza G et al (2009) Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg 96:166–170PubMedCrossRef
22.
Basu S, Chen W, Tchou J et al (2008) Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 112:995–1000PubMedCrossRef
23.
Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast cancer Study. J Am Med Assoc 295:2492–2502CrossRef
24.
Bauer KR, Brown M, Cress RD et al (2007) Descriptive analysis of oestrogen receptor-negative, progesterone receptor-negative and HER 2-negative invasive breast cancer, the so called triple negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728PubMedCrossRef
25.
Kim J, Lee J, Chang E et al (2009) Selective sentinel node plus additional non-sentinel node biopsy based on an FDG PET/CT scan in early breast cancer patients: single institutional experience. World J Surg 33:943–949PubMedCrossRef
Metadaten
Titel
Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors
verfasst von
Pierre Heudel
Sebastien Cimarelli
Anthony Montella
Catherine Bouteille
Thomas Mognetti
Publikationsdatum
01.12.2010
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 6/2010
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-010-0120-3

Weitere Artikel der Ausgabe 6/2010

International Journal of Clinical Oncology 6/2010 Zur Ausgabe

Original Article

Improvement of long-term survival of colorectal cancer in Japanese-Americans of Hawaii from 1990 to 2001

Case Report

Carboplatin and docetaxel-induced acute pancreatitis: brief report

Review Article

Tumor-infiltrating lymphocytes and hepatocellular carcinoma: molecular biology

Case Report

Basal cell carcinoma of the prostate: unusual subtype of prostatic carcinoma

Original Article

Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial

Case Report

Non-muscle invasive bladder cancer with concomitant vaginal urothelial carcinoma: a case report and review of the literature

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise